Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reboxetine + Fluoxetine for obsessive-compulsive disorder
IRCT20090117001556N129Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of reboxetine and fluoxetine in obsessive compulsive disorder (OCD), sponsored by Tehran University of Medical Sciences. Started Jul 2020; status: completed.
02
Drugs
reboxetinefluoxetine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on IRCT20090117001556N129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090117001556N129.